Brief: Incannex Receives Hrec Approval For Phase 2 Clinical Trial Assessing Ihl-675A For Use In Treatment Of Pain And Function In Rheumatoid Arthritis
13/07/2023 14:23
July 13 (Reuters) - Incannex Healthcare Ltd IHL.AX :
* INCANNEX RECEIVES HREC APPROVAL FOR PHASE 2 CLINICAL TRIAL
ASSESSING IHL-675A FOR USE IN TREATMENT OF PAIN AND FUNCTION IN
RHEUMATOID ARTHRITIS
Source text for Eikon: ID:nGNX9s4wvM
Further company coverage: IHL.AX
Recent news on Incannex Healthcare
See all newsBrief: Incannex Healthcare Says Computershare To Be Appointed As US Transfer Agent
Brief: Incannex Healthcare Says Federal Court Of Australia Approved Proposed Schemes Of Arrangement Between Incannex And Its Shareholders
Australia's Incannex up as shareholders in favour of US redomicile
Brief: Incannex Healthcare Will Prepare FDA Ind Application PSI-Gad
Brief: Review Of Ind Application For Ihl-42X By Us FDA Has Been Completed Clinical Trial For Patients With Obstructive Sleep Apnoea May Proceed